Lipoxygenase pathway receptor expression in ovarian cancer

Reproductive Sciences

Volumn 15, Issue 3, 2008, Pages 321-326

  Rocconi, Rodney P ^a,d   Kirby, Tyler O ^b   Seitz, Robert S ^c   Beck, Rod ^c   Straughn Jr , J Michael ^b   Alvarez, Ronald D ^b   Huh, Warner K ^b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Applied Genomics Inc   (United States)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Leukotriene receptors; Lipoxygenase inhibitor; LY293111; Ovarian cancer

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ETALOCIB; LEUKOTRIENE B4 RECEPTOR; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; PARAFFIN; RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; LIPOXYGENASE INHIBITORS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RECEPTORS, LEUKOTRIENE B4; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 42249113159     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719108316390     Document Type: Article

References (27)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin. 2005 ; 55: 10-30.
2. Alberts DS, Green S., Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992 ; 10: 706-717.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 ; 334: 1-6.
4. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 ; 21: 3194-3200.
5. Ding XZ, Talamonti MS, Bell RH Jr, Adrian TE A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs. 2005 ; 16: 467-473.
6. Ara G., Teicher BA Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids. 1996 ; 54: 3-16.
7. Teicher BA, Korbut TT, Menon K., Holden SA, Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol. 1994 ; 33: 515-522.
8. Barnes MN, Chhieng DF, Dreher M., et al. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol. 2005 ; 98: 376-382.
9. Rodriguez-Burford C., Barnes MN, Oelschlager DK, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 2002 ; 8: 202-209.
10. Tang DG, Chen YQ, Honn KV Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A. 1996 ; 93: 5241-5246.
11. el- Hakim IE, Langdon JD, Zakrzewski JT, Costello JF Leukotriene B4 and oral cancer. Br J Oral Maxillofac Surg. 1990 ; 28: 155-159.
12. Bortuzzo C., Hanif R., Kashfi K., Staiano-Coico L., Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta. 1996 ; 1300: 240-246.
13. Hennig R., Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002 ; 161: 421-428.
14. Haraldsdottir S., Guolaugsdottir E., Ingolfsdottir K., Ogmundsdottir HM Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro. Planta Med. 2004 ; 70: 1098-1100.
15. Ding XZ, Iversen P., Cluck MW, Knezetic JA, Adrian JE Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999 ; 261: 218-223.
16. Ghosh J., Myers CE Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A. 1998 ; 95: 13182-13187.
17. Baetz T., Eisenhauer E., Siu L., et al. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs. 2007 ; 25: 217-225.
18. Hennig R., Ventura J., Segersvard R., et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 2005 ; 7: 417-425.
19. Tong WG, Ding XZ, Adrian TE The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002 ; 296: 942-948.
20. Munkarah AR, Genhai Z., Morris R., et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol. 2003 ; 88: 429-433.
21. Harris RE, Beebe-Donk J., Doss H., Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005 ; 13: 559-583.
22. Ding XZ, Adrian TE Role of lipoxygenase pathways in the regulation of pancreatic cancer cell proliferation and survival. Inflammopharmacology. 2001 ; 1-8.
23. Budman DR, Calabro A. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY293111. Anticancer Drugs. 2004 ; 15: 877-881.
24. Hennig R., Ding XZ, Tong WG, Witt RC, Jovanovic BD, Adrian TE Effect of LY293111 in combination with gemcitabine in colonic cancer. Cancer Lett. 2004 ; 210: 41-46.
25. Schwartz GK, Weitzman A., O'Reilly E., et al. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol. 2005 ; 23: 5365-5373.
26. Zhang W., McQueen T., Schober W., Rassidakis G., Andreeff M., Konopleva M. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia. 2005 ; 19: 1977-1984.
27. Tsao MS, Sakurada A., Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005 ; 353: 133-144.